NMN (nicotinamide mononucleotide) is a precursor your body uses to make NAD+, the central coenzyme that powers cellular energy production, DNA repair, and the activity of the sirtuin enzymes that regulate aging. NAD+ levels in skin, blood, muscle, and brain drop substantially as you age, roughly halving between your 30s and 60s, and that decline tracks with most of what we call "feeling older": lower energy, slower recovery, weaker insulin response, slower repair.
Most people take it as a daily anti-aging supplement, betting that propping NAD+ back up restores some of what's lost. The clearest human benefits so far are in older adults and metabolically compromised people: improvements in walking speed, grip strength, aerobic capacity, and muscle insulin sensitivity. If you're in your 20s or early 30s, well-rested, training, and metabolically healthy, the expected benefit is much smaller because your NAD+ is probably still close to baseline. NMN is best understood as a long-game intervention, not something you feel.
Deep-dive
NAD+ is required for hundreds of enzymatic reactions, but the ones that matter most for aging are the sirtuins (SIRT1-7) and PARPs. Sirtuins are NAD+-dependent deacetylases that regulate mitochondrial biogenesis, fat metabolism, inflammation, and DNA repair. PARPs use NAD+ to repair single-strand DNA breaks. Both compete for the same NAD+ pool, and as DNA damage accumulates with age, PARPs consume more NAD+, leaving less for sirtuins. The result is the broad metabolic and inflammatory drift we see in older tissue.
NMN sits one step upstream of NAD+ in the salvage pathway. It's converted to NAD+ by the enzyme NMNAT, which is not rate-limiting, so simply increasing NMN availability raises NAD+ output. The rate-limiting enzyme is actually NAMPT, which makes NMN from nicotinamide. NAMPT activity declines with age, which is the main reason NAD+ falls. Supplementing NMN bypasses this bottleneck.
Bioavailability is messier than the marketing suggests. Oral NMN doesn't travel intact to your tissues. Most of it gets broken down in the gut, either deamidated by gut microbes to nicotinic acid or hydrolysed to nicotinamide, then absorbed and reassembled back into NAD+ in the liver via the salvage pathway. Whether oral NMN has any meaningful advantage over plain old nicotinamide is still genuinely contested. Sublingual and intravenous routes likely deliver more intact NMN, but the human evidence comparing them is thin.
NAD+ does rise. Across multiple human trials at 250 mg/day to 900 mg/day, blood NAD+ increases significantly compared to placebo, with most studies showing dose-dependent increases that plateau around 600 mg. Going from 600 to 900 mg gave no extra NAD+ bump. The question is whether higher blood NAD+ translates into anything you can feel or measure functionally, and the answer is more nuanced.
Muscle and physical performance. This is where the human evidence is strongest. In a 12-week trial in men over 65, 250 mg/day of NMN roughly doubled blood NAD+ and produced significant improvements in gait speed, left-hand grip strength, and the 30-second chair stand test. In a 60-day dose-response trial in middle-aged adults, 600 mg/day showed the best balance of NAD+ elevation and functional improvement on the 6-minute walk test. In amateur athletes given 300, 600, or 1,200 mg/day for six weeks alongside training, aerobic capacity improved dose-dependently, though strength didn't change. A recent meta-analysis of NMN and NR trials in older adults pooled across studies found no significant effect on grip strength, gait speed, or muscle mass, which suggests that the individual positive trials may have been driven by responders rather than uniform effects. The honest summary: some people clearly benefit, especially older or deconditioned ones, but it's not guaranteed.
Insulin sensitivity in women. The cleanest single result in NMN human research came from a 10-week randomised controlled trial in 25 postmenopausal women with prediabetes who were overweight or obese. 250 mg/day of NMN increased muscle insulin sensitivity by roughly 25%, comparable to what you'd get from 10% weight loss or 12 weeks of an insulin-sensitising drug. AKT and mTOR phosphorylation in muscle increased, and genes related to muscle remodeling were upregulated. Notably, fasting glucose, blood pressure, lipids, and liver insulin sensitivity didn't change. The benefit was specific to skeletal muscle. This is one of the few NMN trials that used a hard physiological endpoint (hyperinsulinemic-euglycemic clamp) rather than a self-reported or behavioural measure, which makes it hard to dismiss.
Cardiovascular and other markers. A 12-week trial of 250 mg/day in middle-aged adults found a trend toward reduced arterial stiffness on pulse wave velocity, though it didn't reach statistical significance. Intravenous NMN significantly reduced blood triglycerides in healthy adults. Effects on inflammation markers, lipid panels, and blood pressure have been inconsistent across trials.
What it doesn't do, in humans. Despite the hype, no human trial has shown NMN reverses biological age, extends lifespan, restores hair colour, or rejuvenates skin in any clinically meaningful way. Almost all of the dramatic anti-aging claims come from mouse studies. Mice are not small humans on this; rodents convert NMN to NAD+ very differently and live a fraction as long, so extrapolation is fraught.
Women. Most NMN studies have either been mixed-sex or specifically in postmenopausal women, and the women-specific signal (insulin sensitivity in muscle) is one of the strongest results in the literature. There's no reason to expect different dosing for women. Premenopausal women have higher baseline NAD+ than men of similar age, partly because oestrogen upregulates NAMPT, the enzyme that makes NMN. So premenopausal women may have less room for NMN to add on top, while perimenopausal and postmenopausal women, who lose this oestrogen-driven NAD+ support, are likely the strongest responders. Skip during pregnancy and breastfeeding, the safety data isn't there.
Older adults. This is the population with the most evidence and the largest expected benefit, since NAD+ has dropped furthest from baseline. The trials showing functional improvements (walking speed, grip, aerobic capacity) were done in people 60+, and the muscle insulin sensitivity result was in postmenopausal women. If you're young and healthy, your expected benefit is smaller and the case for daily lifelong supplementation rests more on prevention than on observed effect.
Dosage:
- Standard daily dose: 250-600 mg/day. The 250 mg dose is what most positive human trials have used and is enough to roughly double blood NAD+ in older adults. 600 mg/day showed the best functional results in the dose-response trial and appears to be the practical ceiling, going to 900 mg gave no additional NAD+ benefit
- Timing: Take in the morning. NAD+ has a circadian rhythm, peaking in the morning, and supplementing aligns with that natural cycle. There's some evidence that afternoon dosing may improve lower-limb function in older adults, but morning is the safer default. Avoid taking it late in the day, some people report it being mildly stimulating and disrupting sleep
- With or without food: Either works. NMN absorption isn't strongly food-dependent the way fat-soluble vitamins are. If it causes mild nausea, take with food
- Forms: Plain oral capsules or powder are the most studied and what every positive trial used. Sublingual NMN is marketed as more bioavailable on the theory that it bypasses gut breakdown, but human evidence comparing routes is thin. Liposomal formulations make similar claims with similar lack of head-to-head data. For most people, plain oral NMN at 250-600 mg/day is the defensible choice
- Cycling: Not necessary. Unlike compounds that downregulate receptors with continuous use, NMN feeds a depleted substrate pool. Continuous daily use is the protocol that's been studied
- Stacks: Some people pair with TMG (trimethylglycine) at 500-1000 mg/day on the theory that NAD+ metabolism consumes methyl groups via excreted methylated nicotinamide metabolites, which could in principle deplete methyl donors and raise homocysteine. The mechanistic concern is real but the human evidence that it actually matters at typical NMN doses is weak. If you're already eating adequate folate, B12, and choline, you probably don't need TMG. If you're running NMN at 600 mg+ chronically, adding TMG is cheap insurance
- Older vs. younger users: Older adults (60+) and those with metabolic dysfunction are the population most likely to notice anything. If you're under 40 and metabolically healthy, the realistic expectation is no felt effect, and you're betting on long-term prevention
Here's what you can expect:
For most people, nothing acute. NMN doesn't produce a noticeable effect the way caffeine, modafinil, or even creatine does. You won't feel sharper, more energetic, or younger after a single dose, or after a week.
What the evidence supports, with consistent daily use over 8-12+ weeks: in older adults, modest but measurable improvements in walking speed, grip strength, and aerobic capacity. In postmenopausal or metabolically compromised women, meaningful improvements in muscle insulin sensitivity. In younger, healthy adults, mostly an unfelt rise in blood NAD+ with uncertain functional payoff.
Don't expect the dramatic anti-aging effects you've seen claimed. Those come from mouse studies and they don't transfer cleanly. The realistic frame is that NMN may slow some of the cellular drift that comes with aging, particularly in tissues that have lost the most NAD+. The case is stronger the older you are.
Side effects & risks:
- GI discomfort is the most common side effect. Nausea, bloating, mild stomach upset, especially at doses above 500 mg or on an empty stomach. Take with food if it bothers you
- Headache, flushing, or feeling slightly stimulated can occur in some people, especially when starting. Usually transient. If you get persistent headaches, drop the dose
- Sleep disruption if taken late in the day. Morning dosing is the simple fix
- Methylation concerns at high chronic doses. NAD+ metabolism produces methylated nicotinamide metabolites that the body excretes, which uses up methyl groups. The theoretical concern is that high-dose chronic NMN could raise homocysteine or deplete methyl donors. There's no strong human evidence this happens at 250-600 mg/day, but at higher doses (1g+) chronically, the mechanism becomes more plausible. TMG, choline, folate, and B12 all support methylation if you're concerned
- Active cancer is the main caution. NAD+ is used by all cells, including cancer cells, for DNA repair and energy production. The data is genuinely mixed, some animal studies show NMN doesn't accelerate tumor growth, others show it can in specific cancer types. The mechanistic concern is real (cancers often upregulate NAMPT to feed their own NAD+ demand), and there are no human trials in cancer patients. If you have an active cancer diagnosis or are in remission from an aggressive cancer, avoid NMN until you've discussed it with your oncologist
- Pregnancy and breastfeeding: skip it. No safety data
- Long-term safety data is limited. The longest controlled human trials have run 12-24 weeks. Beyond that, the data thins out. NMN appears safe at typical doses based on what we have, but the multi-decade trajectory is unknown
- Interactions with medications are not well studied. No significant ones have been flagged in the trial literature. Caution if you're on chemotherapy, immunosuppressants, or anything that affects NAD+ metabolism (most chemo agents do)
Blood markers
Fasting glucose, fasting insulin, HbA1c, HOMA-IR, baseline before starting and at 3-6 months. NMN's clearest functional benefit in human trials is muscle insulin sensitivity, this is where you'd expect to see something move if it's working.
Lipid panel (LDL, HDL, triglycerides), baseline and at 3-6 months. Triglycerides in particular have shown reductions in some NMN trials.
hs-CRP and homocysteine, baseline and at 6 months if running higher chronic doses. Homocysteine is the methylation marker to watch, if it rises on NMN, that's the signal to add a methyl donor like TMG.
Liver enzymes (ALT, AST) and kidney function (creatinine, eGFR), baseline. No specific NMN-related concerns documented but standard for any chronic supplementation.
Intracellular NAD+ (PBMC NAD+ assay) is the direct measurement of whether NMN is doing what it's supposed to do. Not standard on most lab panels but available through specialty labs (Jinfiniti, Genova, etc.). Useful at baseline and 3 months if you want to confirm response, but expensive and not strictly necessary if your other markers are moving.
For most people taking NMN at 250-600 mg/day, a baseline metabolic panel and lipid panel before starting and a recheck at 6 months covers the relevant ground. Specialty NAD+ testing is optional, the people who actually benefit from it are those running higher chronic doses or wanting to verify response.
Sold as a dietary supplement in most countries. Reinstated as lawful in US dietary supplements by the FDA in late 2025.
Made with Bullet